Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Mar 1;22(3):983-989.
doi: 10.31557/APJCP.2021.22.3.983.

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women

Ramya Dinnekere Ravi  1 , Jasvinder Kalra  1 , Radhika Srinivasan  2 , Rashmi Bagga  1 , Vanita Jain  1 , Vanita Suri  1 , Naresh Sachdeva  3
Affiliations
Randomized Controlled Trial

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women

Ramya Dinnekere Ravi et al. Asian Pac J Cancer Prev. .

Abstract

Background: Endometrial cancer is the second most frequent genital malignancy in women, which is showing a constant rise all over world. Endometrial hyperplasia is the precursor of endometrial cancer. Levonorgestrel intrauterine system is the first line management in patients with endometrial hyperplasia without atypia. Metformin has shown to reverse endometrial hyperplasia, but its effectiveness and safety in endometrial hyperplasia is uncertain.

Objective: To compare the efficacy in terms of histopathological response, clinical response and safety at the end of 6 months in patients with endometrial hyperplasia without atypia managed with Levonorgestrel intrauterine system alone versus patients managed with Levonorgestrel intrauterine system plus metformin.

Methods: The randomized control trial was conducted on 51 cases of endometrial hyperplasia without atypia. Twenty-five subjects were prescribed metformin 500mg twice daily with Levonorgestrel intrauterine system and 26 subjects, with Levonorgestrel intrauterine system only for 6 months. At the end of 6 months, endometrial sampling was performed for histopathological response.

Results: Clinical response was observed in 23 of 25 subjects in metformin group and 22 of 24 in Levonorgestrel only group. The metformin group responded significantly with amenorrhea (p= 0.0053), while Levonorgestrel only group responded with regular cycles (p=0.027). At the end of study, of 46 subjects available for histopathological evaluation, 100% subjects in metformin group and 95.45% in Levonorgestrel only group (p=0.47826) showed complete response. The metformin group had a significant reduction in body mass index at end of study [P = 0∙023, 95% confidence interval (-1.7802, -0.1418)].

Conclusion: No significant difference in regression of endometrial hyperplasia was observed on adjunctive use of metformin but a significant reduction in BMI was observed. Use of metformin in obese patients may improve the treatment response.

Keywords: Endometrial hyperplasia; Endometrial hyperplasia without atypia; LNG-IUS; Levonorgestrel; Metformin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design Flow Chart
See this image and copyright information in PMC

References

    1. Behery MME, Saleh HS, Ibrahiem MA, et al. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia Without Atypia. Reprod Sci. 2015;22:329–4. - PubMed
    1. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2010;116:92–8. - PMC - PubMed
    1. Carcangiu ML, Kurman RJ, Carcangiu ML, Herrington CS. WHO Classification of Tumours of Female Reproductive Organs. International Agency for Research on Cancer. 2014: 125–6.
    1. Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27:1–25. - PMC - PubMed
    1. Douchi T, Yoshinaga M, Katanozaka M, Mitani M, Nagata Y. Relationship between body mass index and transvaginal ultrasonographic endometrial thickness in postmenopausal women. Acta Obstet Gynecol Scand. 1998;77:905–8. - PubMed

Publication types